Role of interleukin-32 in the mechanism of chronic inflammation in IgG4-related disease and as a predictive biomarker for drug-free remission

References

• Yamamoto M, Takahashi H, Shinomura Y. Mechanisms and assessment of IgG4-related disease: lessons for the rheumatologist. Nat Rev Rheumatol. 2014;10(3):148–59.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Harada S, Ohara M, Suzuki C, Naishiro Y, Yamamoto H, et al. Clinical and pathological differences between Mikulicz's disease and Sjögren's syndrome. Rheumatology (Oxford). 2005;44(2):227–34.
   PubMed Web of Science ®Google Scholar
• Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344(10):732–8.
   PubMed Web of Science ®Google Scholar
• Zen Y, Fujii T, Harada K, Kawano M, Yamada K, Takahira M, et al. Th2 and regulatory immune reactions are increased in immunogloblin G4-related sclerosing pancreatitis and cholangitis. Hepatology. 2007;45(6):1538–46.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Moriyama M, Nakashima H, Miyake K, Hayashida JN, Maehara T, et al. Th2 and regulatory immune reactions contribute to IgG4 production and the initiation of Mikulicz disease. Arthritis Rheum. 2012;64(1):254–63.
   PubMed Web of Science ®Google Scholar
• Umehara H, Nakajima A, Nakamura T, Kawanami T, Tanaka M, Dong L, et al. IgG4-related disease and its pathogenesis-cross-talk between innate and acquired immunity. Int Immunol. 2014;26(11):585–95.
   PubMed Web of Science ®Google Scholar
• Yajima H, Yamamoto M, Shimizu Y, Suzuki C, Naishiro Y, Takahashi H, et al. Possible involvement of toll-like receptor 7-interferon α axis modified with interleukin-21 and thymic stromal lymphopoietin in IgG4-related disease. Ann Hematol. 2015; Sept 17 online first.
   Google Scholar
• Yamamoto M, Yajima H, Takahashi H, Yokoyama Y, Ishigami K, Shimizu Y, et al. Everyday clinical practice in IgG4-related dacryoadenitis and/or sialadenitis: results from the SMART database. Mod Rheumatol. 2015;25(2):199–204.
   PubMed Web of Science ®Google Scholar
• Nakayama M, Niki Y, Kawasaki T, Takeda Y, Ikegami H, Toyama Y, et al. IL-32-PAR2 axis is an innate immunity sensor providing alternative signaling for LPS-TRIF axis. Sci Rep. 2013;3:2960.
   PubMedGoogle Scholar
• Bai X, Kim SH, Azam T, McGibney MT, Huang H, Dinarello CA, et al. IL-32 is a host protective cytokine against Mycobacterium tuberculosis in differentiated THP-1 human macrophages. J Immunol. 2010;184(7):3830–40.
   PubMed Web of Science ®Google Scholar
• Montoya D, Inkeles MS, Liu PT, Realegeno S, Teles RM, Vaidya P, et al. IL-32 is a molecular maker of a host defense network in human tuberculosis. Sci Transl Med. 2014;6(250):250ra114.
   PubMed Web of Science ®Google Scholar
• Netea MG, Azam T, Lewis EC, Joosten LA, Wang M, Langenberg D, et al. Mycobacterium tuberculosis induces interleukin-32 production through a caspase- 1/IL-18/interferon-gamma-dependent mechanism. PLoS Med. 2006;3(8):e277.
   PubMedGoogle Scholar
• Kawano M, Yamada K, Kakuchi Y, Ito K, Hamano R, Fujii H, et al. A case of immunoglobulin G4-related chronic sclerosing sialadenitis and dacryoadenitis associated with tuberculosis. Mod Rheumatol. 2009;19(1):87–90.
   PubMed Web of Science ®Google Scholar
• Heinhuis B, Koenders MI, van de Loo FA, Netea MG, va der Berg WB, Joosten LA. Inflammation-dependent secretion and splicing of IL-32{gamma} in rheumatoid arthritis. Proc Natl Acad Sci USA. 2011;108(12):4962–7.
   PubMed Web of Science ®Google Scholar
• Fantini MC, Monteleone G, Macdonald TT. New players in the cytokine orchestra of inflammatory bowel disease. Inflamm Bowel Dis. 2007;13(11):1419–23.
   PubMed Web of Science ®Google Scholar
• Novick D, Rubinstein M, Azam T, Rabinkov A, Dinarello CA, Kim SH. Proteinase 3 is an IL-32 binding protein. Proc Natl Acad Sci USA. 2006;103(9):3316–21.
   PubMed Web of Science ®Google Scholar
• Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, Matsui S, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD). Mod Rheumatol. 2012;22(1):21–30.
   PubMed Web of Science ®Google Scholar
• Masaki Y, Sugai S, Umehara H. IgG4-related diseases including Mikulicz's disease and sclerosing pancreatitis: diagnostic insights. J Rheumatol. 2010;37(7):1380–5.
   PubMed Web of Science ®Google Scholar
• Mori T, Harada N, Higuchi K, Sekiya Y, Uchimura K, Shimao T. Waning of the specific interferon-gamma response after years of tuberculosis infection. . Int J Tuberc Lung Dis. 2007;11(9):1021–5.
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Funata N, Hayashi N, Eishi Y, Koike M, Tsuruta K, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol. 2003;38(10):982–4.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Takahashi H, Ohara M, Suzuki C, Naishiro Y, Yamamoto H, et al. A new conceptualization for Mikulicz's disease as an IgG4-related plasmacytic disease. Mod Rheumatol. 2006;16(6):335–40.
   PubMedGoogle Scholar
• Masaki Y, Dong L, Kurose N, Kitagawa K, Morikawa Y, Yamamoto M, et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis. 2009;68(8):1310–15.
   PubMed Web of Science ®Google Scholar
• Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, et al. A novel clinical entity, IgG4-related disease (IgG4-RD): general concept and details. Mod Rheumatol. 2012;22(1):1–14.
   PubMed Web of Science ®Google Scholar
• Stone JH, Khosroshahi A, Desphande V, Chan JK, Heathcote JG, Aalberse R, et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum. 2012;64(10):3061–7.
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Yamamoto M, Naishiro Y, Sudoh G, Ishigami K, Yajima H, et al. Necessity of early intervention for IgG4-related disease-delayed treatment induces fibrosis progression. Rheumatology (Oxford). 2013;52(4):679–83.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Harada S, Ohara M, Suzuki C, Naishiro Y, Yamamoto H, et al. Beneficial effects of steroid therapy for Mikulicz's disease. Rheumatology (Oxford). 2005;44(10):1322–3.
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Okazaki K, Kawa S, Ito T, Inui K, Irie H, et al. Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis. J Gastroenterol. 2014;49(6):961–70.
   PubMed Web of Science ®Google Scholar
• Fukui Y, Uchida K, Sakaguchi Y, Fukui T, Nishio A, Shikata N, et al. Possible involvement of toll-like receptor 7 in the development of type 1 autoimmune pancreatitis. J Gastroenterol. 2015;50(4):435–44.
   PubMed Web of Science ®Google Scholar
• Kanno A, Nishimori I, Masamune A, Kikuta K, Hirota M, Kuriyama S, et al. Nationwide epidemiological survey of autoimmune pancreatitis in Japan. Pancreas. 2012;41(6):835–9.
   PubMed Web of Science ®Google Scholar
• Uchida K, Masamune A, Shimosegawa T, Okazaki K. Prevalence of IgG4-related disease in Japan based on nationwide survey in 2009. Int J Rheumatol. 2012;2012:358371
   PubMedGoogle Scholar
• Mikulicz J. Ueber eine eigenartige symmetrishe Erkrankung der Thränen- und Mundspeicheldrüsen. In: Beiträge zur Chirurgie: Festschrift gewidmet Theodor Billroth. Stuttgart, 1892:610–30.
   Google Scholar
• Schaffer AJ, Jacobsen AW. Mikulicz’s syndrome: a report of ten cases. Am J Dis Child. 1927;34:327–46.
   Google Scholar
• Murray CJ, Ortblad KF, Guinovart C, Lim S, Wolock TM, Roberts DA, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9947):1005–70.
   PubMed Web of Science ®Google Scholar
• Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity. 2005;22(1):131–42.
   PubMed Web of Science ®Google Scholar
• Natea MG, Azam T, Ferwerda G, Girardin SE, Walsh M, Park JS, et al. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci USA. 2005;102:16309–14.
   PubMed Web of Science ®Google Scholar
• Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR, et al. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA. 2006;103(9):3298–303.
   PubMed Web of Science ®Google Scholar
• Li D, Chen D, Zhang X, Wang H, Song Z, Xu W, et al. c-Jun N-terminal kinase and and Akt signaling pathways regulating tumour necrosis factor-α induced IL-32 expression in human lung fibrosis: implications in airway inflammation. Immunology. 2015;144:282–90.
   PubMed Web of Science ®Google Scholar
• Ito T, Liu YJ, Arima K. Cellular and molecular mechanisms of P function in human allergic disorders-TSLP programs the ‘t;Th2 code" in dendritic cells. Allergol Int. 2012;61(1):35–43.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Nojima M, Takahashi H, Yokoyama Y, Ishigami K, Yajima H, et al. Identification of relapse predictors in IgG4-related disease using multivariate analysis of clinical data at the first visit and initial treatment. Rheumatology (Oxford). 2015;54(1):45–9.
   PubMed Web of Science ®Google Scholar